Mesoblast Limited
$0.93
24H
Market Cap
Volume
Supply
Price Chart
About Mesoblast Limited - MSB.AX
Mesoblast Limited is a biotechnology company that specializes in developing regenerative medicines based on its proprietary cell-based and mesenchymal precursor cell (MPC) platforms, aiming to treat inflammatory ailments, cardiovascular disease, and back pain. It is headquartered in Australia with international locations and partners involved in the commercialization and development of its product candidates.
What are Mesoblast Limited's core values and mission statement?
Mesoblast Limited's mission is centered on developing innovative regenerative medicine products to treat complex diseases where inflammation plays a significant role. Their core values focus on pioneering medical research and development to transform the lives of patients suffering from these conditions through their cell-based therapies.
Who founded Mesoblast Limited and when?
Mesoblast Limited was founded by Professor Silviu Itescu in 2004.
Who leads Mesoblast Limited?
Mesoblast Limited is led by Dr. Silviu Itescu, who is the company's founder, CEO, and Executive Director.
Where is Mesoblast Limited located, and what is its base country?
Mesoblast Limited is based in Melbourne, Australia.
On which exchanges is Mesoblast Limited traded?
Mesoblast Limited is primarily traded on the Australian Securities Exchange (ASX) under the ticker symbol MSB, and in the United States, it is traded on the Nasdaq under the ticker symbol MESO.
Historical data
Mesoblast Limited (MSB) Price Live Data
The live price of Mesoblast Limited (MSB) is $0.93, with a trading volume of 3,047,702 in the last 24 hours. Wrapstocks updates the MSB price in real-time. Mesoblast Limited is up 5.73% in the last 24 hours. The company has a live market cap of $1,062,364,852.93 and a supply of 1,141,779,959 MSB stocks.
Mesoblast Limited (MSB) is traded on Australia Stock Exchange, and currently, the market is closed; trading will be resumed in 12 hours and 28 minutes.
